Handelsbanken Fonder Ab Adaptive Biotechnologies Corp Transaction History

Handelsbanken Fonder Ab

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 07, 2023	BUY	$6.26 - $9.34 $97,030 - $144,770	15,500 Added 71.76%	37,100 $283,000
Q2 2021 Aug 03, 2021	BUY	$32.22 - $44.59 $9,666 - $13,377	300 Added 1.41%	21,600 $883,000
Q1 2021 Apr 29, 2021	BUY	$37.26 - $67.74 $145,314 - $264,186	3,900 Added 22.41%	21,300 $858,000
Q3 2020 Nov 13, 2020	SELL	$35.79 - $48.81 $78,738 - $107,382	-2,200 Reduced 11.22%	17,400 $846,000
Q2 2020 Aug 13, 2020	BUY	$24.95 - $48.38 $489,020 - $948,248	19,600 New	19,600 $948,000

202

146M

68.8K

42.5K

Ticker ADPT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 142,872,992
Market Cap $849M
Description
Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunoSEQ, a platform and core immunosequencing product that is used to answer translational research questions, as well as to discover new prognostic and diagnostic signal...

Get notified when there are updates to the investment portfolio of Handelsbanken Fonder Ab, based on Form 13F filings with the SEC.

Stay updated on Handelsbanken Fonder Ab with notifications on news.